Citations

Clear

1053 citation(s) found for "Andre, F".

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement
Sidell, Douglas R. , Balakrishnan, Karthik , Best, Simon R. , Zur, Karen B. , Buckingham, Julia C., Alarcón, Alessandro de , Baroody, Fuad M. , Bock, Jonathan M. , Boss, Emily F. , Bower, Charles M. , Clarke, Jeffrey , Clarke, Kevin D., Cocciaglia, Alejandro , Cotton, Robin T., Cuestas, Giselle , Davis, Kara L. , Defagó, Victor, Dikkers, Frederik G. , Dossans, Ines, Guerra, Walter Florez , Fox, Elizabeth , Friedman, Aaron D. , Grant, Nazaneen N. , Hogikyan, Norman D. , Johnson, Kaalan , Johnson, Liane B. , Johnson, Romaine F. , Kelly, Peggy, Klein, Adam M. , Lawlor, Claire M. , Levy, Alejandro G., Licameli, Greg R. , Long, Steve, Manrique, Dayse , McMurray, J. Scott , Meister, Kara D. , Messner, Anna H. , Möhr, Michael , Mortelliti, Anthony J., Novakovic, Daniel , Ongkasuwan, Julina , Piersiala, Krzysztof , Prager, Jeremy D. , Pransky, Seth M. , Raynor, Tiffany , Rodríguez, Hugo, Rodríguez, Verónica P., Scatolini, María Laura , Scheffler, Patrick , Smith, David F. , Smith, Lee P., Smith, Marshall E. , Smith, Richard J. , Sorom, Abraham, Steinberg, Amalia, Stith, John A., Thompson, Dana M. , Thompson, Jerome W. , Varela, Patricio, White, David R. , Wineland, Andre , Yang, Christina J. , Zdanski, Carlton J. , Derkay, Craig S. , Zur, Karen , de Alarcón, Alessandro , Campisi, Paolo , Friedman, Aaron D , Hamdi, Osama , Johnson, Romaine F , Leboulanger, Nicolas , Meister, Kara D , Novakovic, Daniel , Ongkasuwan, Julian , Prager, Jeremy D , Rinkel, Rico N P M , Smith, David F , Wineland, Andre M , Sidell, Douglas R , Davis, Kara L , Balakrishnan, Karthik , Buckingham, Julia, Chen, Sharon , Hamdi, Osama A. , Leboulanger, Nicolas , Lam, Derek J. , Long, Steve, Lott, David G. , Mudd, Pamela A. , Peer, Shazia , Preciado, Diego A. , Russell, John

Mayo Clinic

The Laryngoscope | January 8, 2021 | Volume: 131 | Issue: 6 | Pages: No page available

10.1002/lary.29343 | PMID 33405268 Get It

Objectives/HypothesisThe purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.Study DesignDelphi method‐based survey series.MethodsA multidisciplinary, multi‐institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work‐up.ResultsThe international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).ConclusionThis consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best‐practice applications of systemic bevacizumab for patients with early‐onset or less‐severe disease phenotypes.Level of Evidence5 Laryngoscope, 131:E1941–E1949, 2021
Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis
Speidl, Walter S. , Jaffe, Allan S. , Mair, Johannes , Möckel, Martin , Mueller, Christian, Storey, Robert F. , Vilahur, Gemma , Huber, Kurt , Halvorsen, Sigrun , Geisler, Tobias , Morais, João , Thygesen, Kristian , Storey, Robert F , Huber, Kurt , Thygesen, Kristian , Mockel, Martin , Krychtiuk, Konstantin A , Giannitsis, Evangelos , Gigante, Bruna , Gorog, Diana Adrienne , Jaffe, Allan S. , Wojta, Johann , Lindahl, Bertil

Mayo Clinic

European Heart Journal Acute Cardiovascular Care | December 31, 2020 | Volume: 10 | Issue: 3 | Pages: 343-355

10.1093/ehjacc/zuaa025 | PMID 33620437 Get It

Abstract The formation of a thrombus in an epicardial artery may result in an acute myocardial infarction (AMI). Despite major advances in acute treatment using network approaches to allocate patients to timely reperfusion and optimal antithrombotic treatment, patients remain at high risk for thrombotic complications. Ongoing activation of the coagulation system as well as thrombin-mediated platelet activation may both play a crucial role in this context. Whether measurement of circulating biomarkers of coagulation and fibrinolysis could be useful for risk stratification in secondary prevention is currently not fully understood. In addition, measurement of such biomarkers could be helpful to identify thrombus formation as the leading mechanism for AMI. The introduction of biomarkers of myocardial injury such as high-sensitivity cardiac troponins made rule-out of AMI even more precise. However, elevated markers of myocardial injury cannot provide proof of a type 1 AMI, let alone thrombus formation. The combined measurement of markers of myocardial injury with biomarkers reflecting ongoing thrombus formation might be helpful for the fast and correct diagnosis of an atherothrombotic type 1 AMI. This position paper gives an overview of the current knowledge and possible role of biomarkers of coagulation and fibrinolysis for the diagnosis of AMI, risk stratification, and individualized treatment strategies in patients with AMI.
Polysaccharide from Angelica sinensis attenuates SNP-induced apoptosis in osteoarthritis chondrocytes by inducing autophagy via ERK1/2 pathway
Zhuang, Chao , Li, Chenkai , Wang, Liangliang , Wang, Yuji , Xu, Chao , Ni, Su , Zhao, Gongyin , Jiang, Shijie , Zhu, Ruixia, Wijnen, André J. van

Mayo Clinic

No container title available | December 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-29285/v3 Get It

Abstract ObjectiveChondrocyte apoptosis plays a vital role in osteoarthritis (OA) progression. Angelica sinensis polysaccharide (ASP), a traditional chinese medicine, possesses anti-inflammatory and anti-apoptotic properties in chondrocytes. This study aimed to determine the protective role of ASP on sodium nitroprusside (SNP)-induced chondrocyte apoptosis, and explore the underlying mechanism.MethodHuman primary chondrocytes isolated from articular cartilage of OA patients were treated with SNP alone or in combination with different doses of ASP. Cell viability and apoptosis were assessed, and apoptosis-related proteins including Bcl-2 and Bax were detected. Autophagy levels were evaluated by light chain 3 (LC3)II immunofluorescence staining, mRFP-GFP-LC3 fluorescence localisation and western blot (LC3II, p62, Beclin-1, Atg5). Meanwhile, activation of ERK 1/2 pathway was determined by western blot. The autophagy inhibitors, 3-Methyladenine (3-MA), chloroquine (CQ) and a specific inhibitor of ERK1/2, SCH772984, were used respectively to confirm the autophagic effect of ASP.ResultsThe results showed that SNP-induced chondrocyte apoptosis was significantly rescued by ASP, whereas ASP alone promoted chondrocytes proliferation. The anti-apoptotic effect of ASP was related to the enhanced autophagy and depended on the activation of ERK1/2 pathway.ConclusionASP markedly rescued SNP-induced apoptosis by activating ERK1/2-dependent autophagy in chondrocytes, and it made ASP a potential therapeutic supplementation for OA treatment.
Esophageal motility disorders on high‐resolution manometry: Chicago classification version 4.0 ©
Yadlapati, Rena , Fox, Mark , Bredenoord, Albert J. , Gyawali, C. Prakash , Roman, Sabine , Babaei, Arash , Mittal, Ravinder K. , Rommel, Nathalie , Savarino, Edoardo , Smout, A. J. P. M. , Vaezi, Michael F. , Akiyama, Junichi, Bhatia, Shobna , Carlson, Dustin A. , Chen, Joan W. , Cisternas, Daniel , Cock, Charles , Defilippi, Claudia, Gonlachanvit, Sutep , Hebbard, Geoffrey , Jung, Kee Wook , Katz, Philip O. , Katzka, David A. , Khan, Anzalee , Kohn, Geoffrey P. , Lazarescu, Adriana , Lengliner, Johannes, Omari, Taher , Pohl, Daniel , Richter, Joel E. , Serra, Jordi , Sweis, Rami , Tack, Jan , Tatum, Roger P. , Vela, Marcelo F. , Wu, Justin C. Y. , Xiao, Yinglian , Pandolfino, John E. , Fox, Mark R , Gyawali, C P , Roman, S , Babaei, Arash , Mittal, Ravinder K , Sifrim, Daniel , Smout, André , Zerbib, Frank , Bor, Serhat , Carlson, Dustin A , Cisternas, Daniel , Cock, Charles , de Bortoli, Nicola , Fass, Ronnie , Ghoshal, Uday C , Jung, Kee Wook , Khan, Abraham , Omari, Taher , Park, Moo In , Penagini, Roberto , Serra, Jordi , Tack, Jan , Savarino, Edoardo , Kahrilas, Peter J. , Bor, Serhat , Coss‐Adame, Enrique , Bortoli, Nicola de , Fass, Ronnie , Ghoshal, Uday C. , Hani, Albis Cecilia , Mittal, Sumeet K. , Penagini, Roberto , Tutuian, Radu I. , Wong, Reuben K.

Mayo Clinic

Neurogastroenterology & Motility | December 29, 2020 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/nmo.14058 | PMID 33373111 Get It

Abstract Chicago Classification v4.0 (CCv4.0) is the updated classification scheme for esophageal motility disorders using metrics from high‐resolution manometry (HRM). Fifty‐two diverse international experts separated into seven working subgroups utilized formal validated methodologies over two‐years to develop CCv4.0. Key updates in CCv.4.0 consist of a more rigorous and expansive HRM protocol that incorporates supine and upright test positions as well as provocative testing, a refined definition of esophagogastric junction (EGJ) outflow obstruction (EGJOO), more stringent diagnostic criteria for ineffective esophageal motility and description of baseline EGJ metrics. Further, the CCv4.0 sought to define motility disorder diagnoses as conclusive and inconclusive based on associated symptoms, and findings on provocative testing as well as supportive testing with barium esophagram with tablet and/or functional lumen imaging probe. These changes attempt to minimize ambiguity in prior iterations of Chicago Classification and provide more standardized and rigorous criteria for patterns of disorders of peristalsis and obstruction at the EGJ.
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials
Cohen, Romain , Taı̈eb, Julien , Fiskum, Jack, Yothers, Greg , Goldberg, Richard M. , Yoshino, Takayuki , Alberts, Steven R. , Allegra, Carmen J. , Gramont, Aimery de , Seitz, J. F., Haller, Daniel G. , Erlichman, Charles , Zaniboni, Alberto , Shi, Qian , Goldberg, Richard M , Alberts, Steven R , O'Connell, Michael, Lonardi, Sara , Sinicrope, Frank A , André, Thierry , Shi, Qian , Yoshino, Takayuki , Yothers, Greg , Taieb, Julien , Cohen, Romain , O’Connell, Michael J. , Wolmark, Norman , Lonardi, Sara , Kerr, Rachel , Grothey, Axel , Sinicrope, Frank A. , André, Thierry

Mayo Clinic

Journal of Clinical Oncology | December 23, 2020 | Volume: 39 | Issue: 6 | Pages: 642-651

10.1200/jco.20.01600 | PMID 33356421 Get It

PURPOSE: In patients with stage III colon cancer (CC) whose tumors demonstrate microsatellite instability (MSI), the efficacy of adjuvant fluoropyrimidine (FP) with or without oxaliplatin has not been clearly demonstrated and the prognostic value of MSI remains uncertain. MATERIALS AND METHODS: Individual patient data from the ACCENT database were used to evaluate the effect of FP with or without oxaliplatin on disease-free survival (DFS) and overall survival (OS) among patients with MSI stage III CC and the prognostic value of MSI in patients treated with FP plus oxaliplatin, by stratified Cox models adjusted for demographic and clinicopathological factors. RESULTS: MSI status was available for 5,457 patients (609 MSI, 11.2%; 4848 microsatellite stable [MSS], 88.8%) from 12 randomized clinical trials (RCTs). Oxaliplatin significantly improved OS of MSI patients from the two RCTs testing FP with or without oxaliplatin (n = 185; adjusted hazard ratio [aHR] = 0.52, 95% CI, 0.28 to 0.93). Among the 4,250 patients treated with FP plus oxaliplatin (461 MSI and 3789 MSS), MSI was associated with better OS in the N1 group compared with MSS (aHR = 0.66; 95% CI, 0.46 to 0.95) but similar survival in the N2 population (aHR = 1.13; 95% CI, 0.86 to 1.48; P interaction = .029). The main independent prognosticators of MSI patients treated with FP plus oxaliplatin were T stage (aHR = 2.09; 95% CI, 1.29 to 3.38) and N stage (aHR = 3.57; 95% CI, 2.32 to 5.48). Similar results were observed for DFS in all analyses. CONCLUSION: Adding oxaliplatin to FP improves OS and DFS in patients with MSI stage III CC. Compared with MSS, MSI patients experienced better outcomes in the N1 group but similar survival in the N2 group.
Rare case of symptomatic calcific tendinopathy of the origin of rectus femoris tendon
Jethwa, Tarang , Abadin, Andre A., Pujalte, George , Abadin, Andre, Pujalte, George G A

Mayo Clinic

BMJ Case Reports | December 13, 2020 | Volume: 13 | Issue: 12 | Pages: e236809

10.1136/bcr-2020-236809 | PMID 33318275 Get It

Although calcific tendinopathy of the shoulder is a relatively common clinical diagnosis, calcific tendinopathy of the rectus femoris tendon near its origin at the anterior inferior iliac spine is rare. We present a case of a 53-year-old female avid runner with left hip pain. Clinical evaluation and X-ray imaging led to a diagnosis of calcific tendinopathy of the rectus femoris tendon. The patient was treated conservatively with non-steroidal anti-inflammatory drugs, physical therapy and rest. Calcific tendinopathy of the rectus femoris tendon can occur rarely in active patients and may be a cause of hip pain, responsive to conservative management, but with other treatment options possible if recalcitrant.
Measuring fatigue: a meta‐review
Machado, Myrela O. , Kang, Na‐Young Cindy , Sambhi, Raman D. S., Berk, Michael , Carvalho, André F. , Pérez-Chada, Lourdes M. , Piguet, Vincent , Chada, Lourdes P , Piguet, V , Berk, Michael , Tai, Felicia , Sambhi, Raman-Deep Singh, Merola, Joseph F. , Alavi, Afsáneh

Mayo Clinic

International Journal of Dermatology | December 11, 2020 | Volume: 60 | Issue: 9 | Pages: 1053-1069

10.1111/ijd.15341 | PMID 33301180 Get It

AbstractThere is a lack of validated tools to measure fatigue in patients with inflammatory skin, neuropsychiatric, and medical disorders. The use of nonvalidated tools may compromise the quality of data. The purpose of this meta‐review was to evaluate existing fatigue scales commonly used to assess fatigue in other inflammatory conditions and to identify if there are scales that have been validated in dermatologic conditions. The PubMed/MEDLINE and SCOPUS databases were systematically searched from inception through March 10, 2020, in accordance with the PRISMA statement. Validated tools were identified and assessed according to their main measurement properties. The literature search identified 403 references, and eight studies were eligible and assessed in this review. The unidimensional fatigue scales included were the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT‐F), Brief Fatigue Inventory, Fatigue Severity Scale, Numerical Rating Scale – Fatigue, and Visual Analog Scale – Fatigue. The multidimensional fatigue scales found were the Checklist Individual Strength, Chalder Fatigue Scale, Multidimensional Assessment of Fatigue, Multidimensional Fatigue Inventory Scale, and Piper Fatigue Scale. To measure fatigue, a brief scale with the ability to detect change is needed as there is a growing interest in evaluating this dimension of treatment response. In addition, a good content validity is also needed. From this systematic review, none of the selected scales have had content validation, even though the FACIT was validated in patients with psoriatic arthritis. Validation studies in specific disorders are urgently warranted.
Low‐Dose Tamoxifen Induces Significant Bone Formation in Mice
McGrath, Cody , Sankaran, Jeyantt Srinivas , Styner, Maya , Little, Sarah E , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , Sen, Buer , Styner, Maya , Dudakovic, Amel , Rubin, Janet , Sen, Buer , van Wijnen, Andre J , Xie, Zhihui

Mayo Clinic

JBMR Plus | December 10, 2020 | Volume: 5 | Issue: 3 | Pages: No page available

10.1002/jbm4.10450 | PMID 33778320 Get It

ABSTRACT Use of the selective estrogen receptor modulator Tamoxifen (TAM) is a mainstay to induce conditional expression of Cre recombinase in transgenic laboratory mice. To excise β‐catenin fl/fl in 28‐day‐old male and female Prrx1‐CreER/β‐catenin fl/fl mice (C57BL/6), we utilized TAM at 150 mg/kg; despite β‐catenin knockout in MSC, we found a significant increase in trabecular and cortical bone volume in all genders. Because TAM was similarly anabolic in KO and control mice, we investigated a dose effect on bone formation by treating wild‐type mice (WT C57BL/6, 4 weeks) with TAM (total dose 0, 20, 40, 200 mg/kg via four injections). TAM increased bone in a dose‐dependent manner analyzed by micro–computed tomography (μCT), which showed that, compared to control, 20 mg/kg TAM increased femoral bone volume fraction (bone volume/total volume [BV/TV]) (21.6% ± 1.5% to 33% ± 2.5%; 153%, p < 0.005). With TAM 40 mg/kg and 200 mg/kg, BV/TV increased to 48.1% ± 4.4% (223%, p < 0.0005) and 58% ± 3.8% (269%, p < 0.0001) respectively, compared to control. Osteoblast markers increased with 200 mg/kg TAM: Dlx5 (224%, p < 0.0001), Alp (166%, p < 0.0001), Bglap (223%, p < 0.0001), and Sp7 (228%, p < 0.0001). Osteoclasts per bone surface (Oc#/BS) nearly doubled at the lowest TAM dose (20 mg/kg), but decreased to <20% control with 200 mg/kg TAM. Our data establish that use of TAM at even very low doses to excise a floxed target in postnatal mice has profound effects on trabecular and cortical bone formation. As such, TAM treatment is a major confounder in the interpretation of bone phenotypes in conditional gene knockout mouse models. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Identification of NPTX2 as a prognostic biomarker of Alzheimer’s disease through a longitudinal CSF proteomics study in ADNI subjects
Libiger, Ondrej , Shaw, Leslie M. , Watson, Mark H., Umaña, Kelly L., Canet‐Avilés, Rosa M., Breton, Yannick‐André, Cortes, Laetitia, Chelsky, Daniel , Spellman, Daniel S. , Baker, Susan , Raghavan, Nandini, Potter, William Z., Nairn, Angus C. , Canet-Aviles, Rosa, Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S5 | Pages: No page available

10.1002/alz.047605 Get It

AbstractBackgroundMany biomarkers have been identified which are relevant to studies of Alzheimer’s disease (AD), especially pertaining to the evolution of amyloid plaque, tau tangle pathology and loss of brain tissue. There remains, however, the need for additional biomarkers that reflect pathologic processes affecting neuronal function during pre‐clinical and prodromal stages, to help accelerate drug development efforts.MethodA retrospective investigation of longitudinal changes in concentrations of five analytes (CgA, NPTX2, VGF, SCG2, FABP3) was performed in CSF of ADNI subjects. Rates of longitudinal change in these candidate proteins were compared between: a) Cognitively normal subjects (CN; n = 76) versus subjects with mild cognitive impairment (MCI; n = 111) at baseline; b) Subjects categorized as p‐Tau181/Aβ1‐42 ratio positive versus negative at baseline; and c) ‘Progressors’, i.e., subjects who progressed from CN to MCI or MCI to Dementia within a predefined period versus subjects categorized as ‘non‐progressors’. Following a pre‐specified analysis plan involving mixed‐effects linear models adjusting for relevant covariates, the association between changes in each analyte’s concentration and subjects’ clinical progression was quantified.ResultNPTX2, a protein involved in synaptic function, showed the strongest association with baseline clinical diagnosis of MCI, and a positive p‐Tau181/Aβ1‐42 ratio – the biomarker profile indicative of AD. Differences in the rates of decline in NPTX2 concentration between subjects classified as CN and MCI as well as between p‐Tau181/Aβ1‐42 ratio positive and negative subjects were highly significant (p=0.008 and p<0.0001 resp.), suggesting a complex interaction between the rate of decline in subjects at various stages along the disease continuum. Of the five analytes, only the rates of change in NPTX2 concentrations differed between progressors and non‐progressors (mean difference: 0.08 ± 0.02 ng/mL/year); p = 0.0004), further validating the association of changes in NPTX2 concentration and clinical prognosis. Additional exploratory analyses indicated the presence of a correlation between NPTX2 rates of change and declining cognition measured by MMSE (coef. = 0.3, p = 0.02), and Adas‐Cog 13 (coef. = ‐0.3, p = 0.01).ConclusionThese results suggest that NPTX2 concentration may serve as a prognostic biomarker of accelerated cognitive decline in at least a subset of individuals with AD.